PharmaCyte Biotech (PMCB) EBT (2010 - 2026)

PharmaCyte Biotech (PMCB) has reported EBT for 17 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 199.6% year-over-year to -$2.4 million in Q2 2026; TTM through Apr 2026 was -$6.1 million, a 106.66% decrease from a year earlier, with the FY2026 full-year figure at -$6.1 million, down 106.61% from the prior year.
• EBT was -$2.4 million for Q2 2026 at PharmaCyte Biotech, down from -$1.9 million in the prior quarter.
• Over five years, EBT peaked at -$180346.0 in Q2 2023 and troughed at -$2.4 million in Q2 2026.
• A 5-year average of -$1.2 million and a median of -$952189.0 in 2023 frame the typical range for EBT.
• Across the five-year window, EBT surged 87.31% in 2023 and tumbled 1241.38% in 2024, its largest moves.
• Over 5 years, EBT stood at -$1.9 million in 2022, then jumped by 72.6% to -$515339.0 in 2023, then tumbled by 40.39% to -$723498.0 in 2024, then plunged by 61.67% to -$1.2 million in 2025, then plunged by 107.99% to -$2.4 million in 2026.
• The last three EBT figures came in at -$2.4 million (Q2 2026), -$1.9 million (Q1 2026), and -$1.2 million (Q4 2025), per Business Quant data.